Navigation Links
Osprey Pharmaceuticals Names Jack M. Anthony as CEO
Date:9/26/2007

Co-Founder Phil Coggins to Continue as President and CSO

MONTREAL and SAN FRANCISCO, Sept. 26 /PRNewswire/ -- Osprey Pharmaceuticals, Ltd., a privately held biotechnology company developing first-in-class Leukocyte Population Modulators (LPMs) for serious, chronic diseases, announced today the appointment of Jack M. Anthony to Chief Executive Officer. Dr. Philip Coggins, who previously held the position of CEO will continue as President and assume the new role of Chief Scientific Officer. Mr. Anthony will be based in San Francisco, where Osprey has located most administrative functions, while concentrating its laboratory and R&D operations in Montreal, Canada.

"I am pleased to announce that Jack will take the helm of Osprey Pharmaceuticals and assume additional responsibilities as CEO," said Philip Coggins, President and co-founder of Osprey. "Looking at the powerhouse of talent assembled at Osprey, this transition is a 'no-brainer,' and as a neurochemist I'm qualified to say that. With Jack as CEO and with the recent addition of Dr. Barbara Finck as Chief Medical Officer, we have the key individuals in place to take Osprey to the next level."

"These changes will best leverage the extensive experience and track record of the senior management team at Osprey," said Janice LeCocq, Chairman of the Board. "This time next year we expect to have the first clinical proof of concept of our LPMs in the treatment of renal disease (glomerulonephritis, or GN). By validating a new treatment modality, we expect to open up a broad array of other clinical targets, building towards clinical and commercial success."

Mr. Anthony began his career in healthcare with Baxter Healthcare and served the company for over 16 years, rising through the ranks to become Vice President in the Blood Therapy Group. In the 20 years since Baxter, he has held various senior executive positions in a number of biotechnology companies including Applied Immune Sciences (now part of Sanofi-Aventis), Inhale (now Nektar), FibroGen and Tularik (acquired by Amgen). Mr. Anthony was also CEO of Pharmix, a computational chemistry company in the San Francisco area. Most recently, Mr. Anthony served as Osprey's Senior Vice President, Corporate Development.

"This is an exciting time for us as we plan to enter clinical testing with our first product early next year and forge key partnerships around specific fusion proteins emerging from our LPM platform," said Mr. Anthony. "I believe we are in an incredibly strong position to manage multiple clinical trials as we advance our development pipeline and to engage experienced partners where a strategic collaboration is the best means to achieve late-stage development and commercialization."

About Osprey Pharmaceuticals Ltd.

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes. The company expects to initiate its first Phase Ib trial for chronic kidney disease in early 2008.

Osprey has a highly productive R&D engine and has developed a portfolio of 12 preclinical product candidates addressing a variety of diseases including cancer, cardiovascular disease, and neurological disorders. The company anticipates initiating at least one clinical trial annually over the next three years. Osprey minimizes the risks inherent in drug development by using a technology with the capability to address immune system dysfunction system- wide, and then uniformly applying standardized testing and manufacturing protocols across its portfolio. Osprey Pharmaceuticals is based in Montreal, Canada and can be found online at http://www.ospreypharma.com .

Contacts:

Jack M. Anthony

CEO

anthony@ospreypharma.com

Justin Jackson or John Cummings of Burns McClellan on behalf of Osprey

jjackson@burnsmc.com

jcummings@burnsmc.com

Tel: 212-213-0006

Robert Wagstaff

Vice President, Finance

wagstaff@ospreypharma.com

Tel: 514-336-3118


'/>"/>
SOURCE Osprey Pharmaceuticals, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Wisconsin IT association names Gee president, CEO
4. Quintessence Biosciences names new president
5. CDW names VP to handle Berbee merger
6. NimbleGen names CFO with capital-raising past
7. Cisco names Berbee a top partner of 2005
8. Cisco names Inacom most innovative partner
9. UW-Madison medical school names new dean
10. GE Healthcare names new CEO
11. Bruker AXS names new leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):